Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 23 of 23 publications.

Keogh KA, Dolin P, Kielar D, Shavit A, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen SY. Pulmonary and cardiovascular involvement and persistent damage in eosinophilic granulomatosis with polyangiitis: a retrospective analysis of US health insurance claims data. Poster presented at the CHEST 2024; October 9, 2024. Boston, MA. [abstract] Chest. 2024 Oct; 166(4, Suppl):A5373-A57.

Ayad M, Karanth S, Patel B. A quality improvement initiative to determine the outcomes of creating an automated repeat lactate order in sepsis patients with lactate levels greater than or equal 2 mmol/l. Poster presented at the CHEST 2018 Annual Meeting; October 2018. [abstract] Chest. 2018 Oct; 154(4):321A. doi: 10.1016/j.chest.2018.08.294

Simou E, Leonardi-Bee J, Britton J. The effect of alcohol consumption on the risk of ARDS: a systematic review and meta-analysis. Chest. 2018 Jul;154(1):58-68. doi: 10.1016/j.chest.2017.11.041

Sanchez-de-la-Torre A, Soler X, Barbe F, Flores M, Maisel A, Malhotra A, Rue M, Bertran S, Aldoma A, Worner F, Valls J, Lee CH, Turino C, Galera E, de Batlle J, Sanchez-de-la-Torre M, Spanish Sleep Network. Cardiac troponin levels in patients with acute coronary syndrome and sleep apnea: a pilot study. Chest. 2018 Feb;153(2):329-38. doi: 10.1016/j.chest.2017.06.046

Donohue J, Ganapathy V, Davenport E, Nelson L, Zhao X. COPD-related hospitalizations associated with arformoterol tartrate treatment among patients receiving concomitant tiotropium (TIO) therapy: post hoc analyses from a 52-week randomized, controlled study. Poster presented at the CHEST 2016 Annual Meeting; October 24, 2016. Los Angeles, CA. [abstract] Chest. 2016 Oct; 150(4_S). doi: 10.1016/j.chest.2016.08.990

Ford LB, Matz J, Hankinson T, Prillaman B, Georges G. A comparison of fluticasone propionate nasal spray and cetirizine in ragweed fall seasonal allergic rhinitis. Allergy Asthma Proc. 2015 Jul;36(4):313-9. doi: 10.2500/aap.2015.36.3860

White MV, Hogue SL, Bennett ME, Goss D, Millar K, Hollis K, Siegel PH, Wolf RA, Wooddell M, Silvia S. EpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting. Allergy Asthma Proc. 2015 Jul;36(4):306-12. doi: 10.2500/aap.2015.36.3859

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Katial RK, Oppenheimer JJ, Ostrom NK, Mosnaim GS, Yancey SW, Waitkus-Edwards KR, Prillaman BA, Ortega HG. Adding montelukast to fluticasone propionate/salmeterol for control of asthma and seasonal allergic rhinitis. Allergy Asthma Proc. 2010 Jan;31(1):68-75. doi: 10.2500/aap.2010.31.3306

Andrews CP, Martin BG, Jacobs RL, Mohar DE, Diaz JD, Amar NJ, Kaiser HB, Vandewalker ML, Bernstein J, Toler WT, Prillaman BA, Dalal AA, Lee LA, Philpot EE. Fluticasone furoate nasal spray is more effective than fexofenadine for nighttime symptoms of seasonal allergy. Allergy Asthma Proc. 2009 Mar;30(2):128-38. doi: 10.2500/aap.2009.30.3204

Rodriguez E, Ferrer J, Marti S, Zock JP, Plana E, Morell F. Impact of occupational exposure on severity of COPD. Chest. 2008 Dec;134(6):1237-43.

Massanari M, Sacco P, Kianifard F, Maykut R, Zeldin R. Addition of omalizumab improved measures of impairment associated with moderate-severe persistent asthma. Poster presented at the American College of Chest Physicians; October 2008. Philadelphia, PA. [abstract] Chest. 134(4_MeetingAbstracts):95001.

Santanello NC, DeMuro-Mercon CJ, Shah SR, Schenkel EJ, Ratner PH, Norquist JM, Philip G. Validation of the nighttime symptoms score as a clinically relevant measure of allergic rhinitis. Allergy Asthma Proc. 2006 May 1;27(3):231-9.

Delea T, Hagiwara M, Borker R, Stanford R. Observational study of the risk of ED visit or hospitalization in COPD patients receiving maintenance therapies: a time-dependent analysis. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):178S. doi: 10.1378/chest.128.4_MeetingAbstracts.178S-a

Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, Dorinsky PM, Nelson HS. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005 Oct;128(4):1910-20. doi: 10.1378/chest.128.4.1910

Borker RD, Watkins M, Knobil K, Emmett A, Kalberg C. Using distribution-based standard error of measurement (SEM) method to determine minimal important difference (MID) for the symptom status index (SSI). Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physicians; October 29, 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 supplement):251S.

Borker RD, Hayflinger C, Stanford R. Risk of hospitalization/emergency visit in patients with chronic obstructive pulmonary disease by initial medication regimen. Poster presented at the CHEST 2005: 71st Annual Meeting of the American College of Chest Physician; October 2005. [abstract] Chest. 2005 Oct; 128(4 Supplement):257S.

Riedel A, Chastek B, Borker RD. Healthcare and economic burden in undiagnosed chronic obstructive pulmonary disease (COPD) patients. Presented at the 71st Annual Chest International Meeting; October 2005. Montreal, Canada. [abstract] Chest. 2005 Oct; 128(4 Supplement):123S.

Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest. 2005 Jan 1;127(1):89-97.

Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA, Klein KC, Rickard KA. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc. 2004 Mar;25(2):115-20.

Fischer TL, Borker R, Barnhart F, Morris A, Zhu J. Effect of cilomilast on chronic obstructive pulmonary disease (COPD) patients with impaired quality of life (QOL). Presented at the 69th Annual Chest International Meeting; January 2003. Orlando, FL. [abstract] Chest. 2003 Jan; 124(4 Supplement):129S. doi: 10.1378/chest.124.4_MeetingAbstracts.129S

Allen DB, Meltzer EO, Lemanske, Jr. RF, Philpot EE, Faris MA, Kral KM, Prillaman BA, Rickard KA. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002 Nov;23(6):407-13.

Ratner PH, Howland, 3rd WC, Jacobs RL, Reed KD, Goode-Sellers ST, Prillaman BA, Philpot EE, Cook CK. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc. 2002 Jul;23(4):259-63.